Free Trial

Kronos Bio 8/8/2024 Earnings Report

Kronos Bio logo
$0.99 -0.02 (-1.92%)
As of 01/17/2025 04:00 PM Eastern

Kronos Bio EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
$2.69 million
Expected Revenue
$1.75 million
Beat/Miss
Beat by +$940.00 thousand
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Kronos Bio Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Kronos Bio Inc Ordinary Shares
Kronos Bio announces workforce reduction of 83% by year-end
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat